Senate Finance Dives Deeper Into PBM Weeds, Including Brand Over Generic Preferences

New draft legislation does not include proposal to force PBMs to cover and put generics and biosimilars on lower cost-sharing tiers than their more expensive branded counterparts.

three-tied cake
The Senate Finance Committee wants PBM justification of brand vs. generic, biosimilar tiering preferences. • Source: Shutterstock

The Senate Finance Committee's pharmacy benefits management (PBM) reform legislation would document the frequency and cost of health plans favoring higher-priced brand medicines over their generic and biosimilar equivalents in Medicare.

The new transparency requirements may help prevent plans from favoring higher list price products to capture more rebates at the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet